Clinical Trials Logo

Filter by:
NCT ID: NCT05740748 Not yet recruiting - Asthma, Allergic Clinical Trials

Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.

NCT ID: NCT05729802 Not yet recruiting - Clinical trials for Educational Problems

The Holographic Standardized Patient

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The current pandemic has revealed in-person simulation training and evaluation is vulnerable to disruption, and alternatives are needed which allow remote evaluation. The recently developed Microsoft Hololens headset device allows interactable holograms to be inserted into a user's workspace (mixed reality) - permitting the augmentation of existing clinical and training spaces with holographic (i.e. virtual) patients via the prototype HoloSIM software. This study is the first known research initiative aiming to demonstrate the feasibility and effectiveness of mixed reality for acute medicine training and assessment at a distance. Space, time, personnel, pandemic, and cost constraints limit opportunities for high-fidelity simulation exercises for post-graduate trainees at Sunnybrook. By developing and demonstrating the effectiveness of this new training modality, increased simulation exercises will lead to a higher quality education experience, better functioning teams, and better patient outcomes.

NCT ID: NCT05729503 Not yet recruiting - Anxiety Clinical Trials

Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals

Start date: May 6, 2026
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effect of a sphenopalatine ganglion (SPG) block in anxious patients at electronic dance music festivals. The main question is: - Is an SPG block useful in reducing anxiety, in comparison to placebo? Participants will have lidocaine-soaked cotton tip applicator placed inside each nare for 10-minutes, or have a saline-soaked cotton tip applicator placed inside each nare for 10-minutes. Researchers compare the lidocaine-soaked intervention (SPG block) with the saline-soaked intervention (placebo) to see if it reduces anxiety in patients presenting at electronic dance music festivals with anxiety.

NCT ID: NCT05724888 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Physical Activity and CVD in Adolescents With Type 2 Diabetes

CVD
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The main research questions for this study are: (1) Is delivering a resiliency-informed behavioural intervention designed to increase physical activity (PA) feasible for adolescents living with Type 2 Diabetes (T2D)? and (2) What is the expected change in proposed cardiovascular outcomes after 12 weeks in both study arms? Qualitative and quantitative methods embedded in this pilot randomized trial will answer these questions and determine the feasibility of a larger randomized controlled trial.

NCT ID: NCT05715814 Not yet recruiting - Clinical trials for End Stage Kidney Disease

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

CANARY
Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

NCT ID: NCT05714397 Not yet recruiting - Clinical trials for Anterior Knee Pain Syndrome

Effectiveness of Cingal™ for Improving Pain Scores and Function in Anterior Knee Pain

Start date: April 2023
Phase: N/A
Study type: Interventional

Anterior Knee Pain (AKP) is a common condition that can be challenging to treat effectively. The main goal of treatment regimens is to improve the function of the knee. However, treatment can be challenging due to the knee pain experience. Cingal™ contains hyaluronic acid (HA), which acts as a joint lubricant, and the corticosteroid triamcinolone hexacetonide (TH). Some studies have shown that Cingal™ can improve joint function and provide short-term pain relief.

NCT ID: NCT05713630 Not yet recruiting - Subdural Hematoma Clinical Trials

The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma

TRACE
Start date: July 2024
Phase: Phase 3
Study type: Interventional

Subdural hematoma (SDH) is a common condition experienced after head injury. Blood collects on the surface of the brain, causing headaches which can progress to confusion, weakness, or even coma. While patients with SDH often receive surgery, not all patients require surgery right away to ease pressure on the brain. After surgery, there can be up to 30 percent chance of more bleeding and the need for more surgeries. Given this, a drug capable of lowering the chance of more bleeding and speeding the recovery of the patient is highly desirable. In this study, we will test a commonly used, cheap drug called Tranexamic Acid (TXA). While the body stops unwanted and sometimes dangerous bleeding naturally by forming blood clots, TXA stops these blood clots from breaking down, which helps to keep bleeding spots plugged. Our previous study showed that TXA helped speed up patients' recovery; but a larger number of patients is necessary to evaluate how well TXA works to reduce bleeding and improve patient-reported outcomes. In this study, regardless of the need for surgery, half of the patients will be randomly assigned to take TXA, while the other half will take a placebo, which is a look-alike substance that contains no active drug. We will measure multiple outcomes over time to determine if TXA is working and lowers healthcare and personal costs, while also taking blood and surgical samples, to better understand how this drug works in SDH patients.

NCT ID: NCT05704699 Not yet recruiting - Clinical trials for eTRE (Early Time Restricted Eating)

Effect of Early Eating and Stair Climbing on Body Composition

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

To our knowledge, as of this day there are only four studies which examined the effects of eTRE with a duration of 12 weeks. There are no studies that examined this phenomenon beyond 12 weeks, one study that lasted five weeks and four studies that lasted 4 weeks or less, some even days. The four studies that lasted 12 weeks in duration all have opportunities to improve upon, which will be discussed here. The first study performed by Gabel et al., focused primarily on measuring body weight, not body composition in older adults. The eating window also began later in the morning at 1000h and finished at 1800h. There also was no restriction on participants consuming caffeine during the fasting window. The second study conducted by Gasmi et al., was focused on strictly older male participants that were active and healthy, again, without measuring body composition. The third study conducted by Wilkinson et al., did not measure body composition and the eating window lasted 10 hours instead of 8. The fourth study performed by Chow et al., examined eTRE with adults aged 45+/-12 years old and did not mention any exclusion criteria based upon physical activity levels or restrictions on caffeine/artificial sweetener intake during the fasting window. Furthermore, none of the studies mentioned above examined eTRE against eTRE with Brief Intense Stair Climbing (BISC) directly. We believe that the proposed study will address the concerns mentioned previously and further knowledge associated with eTRE.

NCT ID: NCT05703763 Not yet recruiting - Clinical trials for Giant Cell Arteritis

Applanation Tonometry in the Diagnosis of Giant Cell Arteritis

TAAT
Start date: March 2024
Phase:
Study type: Observational

The objective of this observational prospective cohort study is to assess if: 1. temporal artery stiffness measurement by applanation tonometry may help predict a final diagnosis of new-onset GCA 2. In patients with a diagnosis of GCA, identify if temporal artery stiffness measured by applanation tonometry improves with treatment.

NCT ID: NCT05703360 Not yet recruiting - Stroke Clinical Trials

Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance

Re:DriVR
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness of an immersive virtual-reality (IVR) based stimulation program, in improving visual perception for people who have lost their driver's license due to perceptual or cognitive impairments. The main questions it aims to answer are: 1. Can the 6-week IVR stimulation program help improve driving performance? 2. Will participants experience improvement in visual detection and perception after training? Study Design Summary: - Participants will be randomized into a waitlist group or intervention-first group - The VR-based intervention will consist of training every 2 days for six weeks - Waitlist group will wait 6 weeks before starting intervention at study midpoint (week 7) - Intervention-first group will begin with intervention (week 1-6) and then stop intervention at study midpoint - Participants will complete tests related to driving performance, visual attention, and visual fields at the start of study, midpoint, and end of study Researchers will analyze data for changes from baseline in outcome measures.